Status and challenge of vaccine research for Clostridiodes difficile in clinical trials
10.13200/j.cnki.cjb.003981
- VernacularTitle:艰难梭菌疫苗临床试验的研究现状及挑战
- Author:
TAO Wei
- Publication Type:Journal Article
- Keywords:
Clostridiodes difficile(C. difficile);
Antibiotic-associated diarrhea(ADD);
Vaccine;
Endotoxin;
Monoclonal antibody(mAb)
- From:
Chinese Journal of Biologicals
2023;36(9):1138-1142
- CountryChina
- Language:Chinese
-
Abstract:
Clostridiodes difficile(C.difficile)is the most common causative agent of antibiotic-associated diarrhea(ADD)in the world. In recent years,with the emergence of highly resistant and virulent strains,the outbreaks of C.difficile infection have occurred around the world. The incidence,recurrence and mortality of C.difficile infection are on the rise worldwide,and bring great challenges to clinical treatment. Pathogenic strains mainly produce two homologous glycosylation toxins A and B,which can cause symptoms ranging from diarrhea to highly lethal toxic megacolon. In view of the malignant consequences caused by C.difficile infection,disease prevention is still an important way worth exploring. Until now there is no approved vaccine against C.difficile. Therefore,this review assessed the status and challenge of clinical trials of vaccine research for C.difficile.
